Article
Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires
Neutral
0.0
−100 Bearish
0
+100 Bullish
Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This